Nuvalent, Inc.
NUVL
Pozycja w akcjach
#2111
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Cena akcji
$123.96
Ostatnia synchronizacja: 2026-07-21
Kapitalizacja rynkowa
$9.75B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
27.56%
Kraj
US
Handel Nuvalent, Inc. (NUVL)
Kategoria
Healthcare
Zyski dla Nuvalent, Inc. (NUVL)
Zyski w Mar 2026 TTM: $-449.48M
Według najnowszych raportów finansowych Nuvalent, Inc., obecny zysk firmy wynosi $-449.48M. W roku 2023 firma osiągnęła zysk w wysokości $-126.22M, spadek w porównaniu do zysku z roku 2022, który wynosił $-81.85M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Nuvalent, Inc. od 2019 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-449.48M | 72.88% |
| 2024 | $-259.99M | 105.98% |
| 2023 | $-126.22M | 54.20% |
| 2022 | $-81.85M | 76.65% |
| 2021 | $-46.34M | 218.34% |
| 2020 | $-14.56M | 23.26% |
| 2019 | $-11.81M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -1,273.56% |
US
|
|
| $-3.09B | 586.80% |
US
|
|
| $-4.02B | 793.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -533.98% |
NL
|
